Promoter Ravi Agrawal has released the pledge on 1,60,000 equity shares of Ajanta Pharma Limited, reducing the encumbered holdings held by the Ravi Agrawal Trust. The release, attributed to excess pledge, was executed on June 30, 2026, and disclosed to the stock exchanges on the same day. This transaction reduces the trust's total encumbered shares, which were previously pledged for business financing purposes with Infina Finance Private Limited.

The shares were held in the demat account of Barclays Securities (India) Private Limited. The details of the release were submitted in the prescribed format under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing was signed by Ravi Purushottam Agrawal and submitted to BSE Limited and the National Stock Exchange of India.

Prior to this release, Ravi Agrawal, as trustee of the Ravi Agrawal Trust, held 1,697,696 encumbered shares, representing 1.36% of the total share capital of the company. Following the release of 1,60,000 shares, the post-event holding of encumbered shares stands at 1,537,696 shares, which is 1.23% of the total share capital.

The disclosure confirmed that other promoters, including Gabs Investments Pvt Ltd, Yogesh M Agrawal, Mannalal B Agrawal, Rajesh M Agrawal, Aayush M Agrawal, and Ganga Exports, did not report any changes in their encumbrance status during this period.

The following table details the specific release of pledge transaction:

Ajanta Pharma Limited achieved two significant milestones in FY 2025-26, with consolidated revenue surpassing ₹5,000 crore and net profit crossing ₹1,000 crore. The specialty pharmaceutical company, which operates across Branded Generics in India, Asia, and Africa, as well as Generics in the US and an Antimalarial Institutional business in Africa, delivered broad-based growth across all segments during the year.

Key Financial Highlights

The company's consolidated financial performance for FY 2025-26 reflects strong top-line and bottom-line growth, underpinned by disciplined cost management and sustained demand across markets. The following table summarises the key financial metrics:

Export markets remained a key growth engine, contributing 69% of total revenue. The Branded Generics business contributed 68% of overall revenue, spread across India, Asia, and Africa.

Segment-Wise Performance

Growth was well-diversified across geographies and business verticals during FY 2025-26.

India Business: The India business grew approximately 15% in FY 2026, outperforming the Indian Pharmaceutical Market (IPM) growth rate of 10% as per IQVIA MAT March 2026 by 324 basis points. The outperformance was driven by 26 new product launches, including 5 first-to-market introductions. Ajanta Pharma improved its IQVIA ranking to 24th from 26th in the previous year. The company added around 300 medical representatives, taking the total India field force to approximately 3,750.

US Generics: The US Generics business recorded exceptional 49% growth, supported by 8 new product launches in the last 15 months. As of the reporting period, the company had 49 products on the shelf with 19 ANDAs awaiting approvals. During the year, 5 ANDAs were filed, 4 final approvals were received, and 3 products were launched.

Emerging Markets: The Africa Branded Generics market registered robust 15% growth, while Asia was impacted by the Middle Eastern conflict, recording a slight decline of 1%. The company added 250+ medical representatives in these markets, taking total MR strength to over 2,250.

Africa Institutional: The Antimalarial Institutional business grew 9% for the year, ahead of initial expectations, supported by improved order flows from procurement agencies in the second half.

Standalone Financial Performance

On a standalone basis, Ajanta Pharma also delivered solid results for FY 2025-26:

Foreign exchange earnings stood at ₹2,994.66 crore (previous year ₹2,871.82 crore), while foreign exchange outgo was ₹549.92 crore (previous year ₹487.20 crore).

R&D and Sustainability Initiatives

Research and development remained a strategic priority, with total R&D spend of ₹260.37 crore, comprising capital expenditure of ₹8.79 crore and recurring expenditure of ₹251.58 crore, representing 4.77% of consolidated turnover. Key R&D initiatives included development of complex generics for ANDA filings, novel drug combinations, advanced ophthalmic formulations, and transition of tablet coatings from non-aqueous to aqueous systems.

On the sustainability front, renewable sources fulfilled 34% of the company's energy requirements during FY 2026, supported by the installation of an additional 3.8 MW solar power plant, bringing total solar capacity to 16.6 MW from 12.6 MW in the prior year. The company reduced carbon emissions by 11,590 tonnes of CO2 through renewable energy and energy-efficiency measures. Two biomass boilers were commissioned at Dahej and Paithan sites. A water conservation project in the Marathawada region generated a conservation potential of 1.5 lakh KL per annum. The company also achieved Zero Liquid Discharge across operations, ensuring 100% wastewater recycling and reuse.

Corporate Developments and Governance

The Board declared an interim dividend of ₹28 per equity share for FY 2025-26. The paid-up share capital at the end of FY 2026 stood at ₹24,98,71,248, comprising 12,49,35,624 equity shares of ₹2 each. During the year, 23,525 equity shares were allotted under the Share-Based Incentive Plan 2019.

Ajanta Pharma Ireland Limited was incorporated during the year as a wholly owned subsidiary, further strengthening the company's international presence. The company's credit ratings were reaffirmed at CARE AA+ (long-term) and CARE A1+ (short-term) by CARE Ratings.

The company's CSR spend for FY 2025-26 totalled ₹23.73 crore, exceeding the statutory obligation of ₹20.01 crore. Initiatives spanned healthcare, education, community welfare, and sports promotion. The company also launched Ajanta Academy, a digital learning management system, to strengthen capability development across functions. As of 31 March 2026, the company had more than 11,000 employees and was certified as a Great Place to Work for the fourth consecutive year. The company was also recognised as the 'Most Preferred Workplace for Women' during the year.

In August 2025, the Income Tax Authorities carried out search operations at certain premises of the company. The company received a notice under Section 158BC of the Income-tax Act, 1961 for the block period 1 April 2019 to 17 November 2025. The company filed the return for the said block period on 6 April 2026, with no undisclosed income reported. The consequent impact on the financial statements, if any, is currently not ascertainable.

Annual General Meeting

The Forty-Seventh Annual General Meeting of Ajanta Pharma Limited is scheduled for Thursday, July 16, 2026, at 11:00 a.m. through Video Conferencing/Other Audio-Visual Means. Key agenda items include adoption of audited financial statements for FY 2025-26, confirmation of the interim dividend, re-appointment of Mr. Mannalal B. Agrawal as a Non-Executive Non-Independent Director, and ratification of remuneration of cost auditors at ₹7.80 lakhs plus GST for FY 2026-27.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE031B01049/63e07228-8a58-4f1a-8e83-b3928128fa20.pdf